Anzeige
Mehr »
Login
Dienstag, 22.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Der Megatrend 2025: Die unterschätzte Chance im Uranmarkt - was diese Aktie JETZT interessant macht!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LCUJ | ISIN: FR0010331421 | Ticker-Symbol: IDD
Tradegate
22.04.25
08:05 Uhr
1,748 Euro
-0,004
-0,23 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
INNATE PHARMA SA Chart 1 Jahr
5-Tage-Chart
INNATE PHARMA SA 5-Tage-Chart
RealtimeGeldBriefZeit
1,7261,73211:49
1,7161,74211:49

Aktuelle News zur INNATE PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiInnate Pharma SA - 6-K, Report of foreign issuer1
MiInnate Pharma SA: Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition285Innate to propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to a CEO/board of directors ...
► Artikel lesen
MiInnate Pharma SA: Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025275Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") will hold its annual general meeting of shareholders ("AGM") at 10:30 a.m. CEST on May 22, 2025...
► Artikel lesen
03.04.Innate Pharma SA - 6-K, Report of foreign issuer-
INNATE PHARMA Aktie jetzt für 0€ handeln
03.04.Innate Pharma SA: Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum249Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its executive team will present and host 1x1 meetings at the Stifel...
► Artikel lesen
29.03.Innate Pharma S.A. (NASDAQ:IPHA) Q4 2024 Earnings Call Transcript1
28.03.H.C. Wainwright maintains Buy rating on Innate Pharma stock1
27.03.Innate Pharma SA - 6-K, Report of foreign issuer-
27.03.Innate Pharma reports FY results3
27.03.Innate Pharma SA: Innate Pharma Reports Full Year 2024 Financial Results and Business Update302FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome New data, including lacutamab improved health-related quality of life data from...
► Artikel lesen
26.03.Innate Pharma SA: Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting276IPH4502 is a novel and differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors. IPH4502 demonstrated preclinical anti-tumor...
► Artikel lesen
25.03.Innate Pharma SA: Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference326Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its executive team are scheduled to participate in the upcoming...
► Artikel lesen
20.03.Innate Pharma SA - 6-K, Report of foreign issuer1
20.03.Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results292Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announces that the Company will hold a conference call on Thursday, March 27, 2025 at 2...
► Artikel lesen
27.02.Innate Pharma SA - 6-K, Report of foreign issuer-
27.02.Innate Pharma SA: Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference315Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its executive team will present and host 1x1 meetings at the Leerink...
► Artikel lesen
18.02.Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments1
18.02.Innate Pharma SA - 6-K, Report of foreign issuer-
17.02.Innate Pharma: FDA Grants Breakthrough Therapy Designation To Lacutamab For R/R Sezary Syndrome8
17.02.Innate Pharma SA: Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome449Designation is based on TELLOMAK Phase 2 results demonstrating efficacy and a favorable safety profile in patients with advanced Sézary syndrome heavily pre-treated, post- mogamulizumab. ...
► Artikel lesen
Seite:  Weiter >>
66 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1